The BioProtect Balloon Spacer significantly preserves bowel, urinary, and sexual quality of life in prostate cancer patients undergoing radiation therapy over four years. The study showed ...
TRAVERSE trial showed no increase in MACE with testosterone therapy, improving sexual function and depression symptoms without affecting diabetes or prostate cancer outcomes. T4DM trial found a 13% ...
An expert discusses how proactive referral, multidisciplinary coordination, and early identification can optimize outcomes for patients with muscle-invasive bladder cancer, especially those with ...
LUGPA president Scott B. Sellinger, MD, FACS, highlights the key priorities and sessions at this year's LUGPA Annual Meeting. Stay current with the latest urology news and practice-changing insights — ...
Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape. In this interview, conducted at the 2025 LUGPA Annual Meeting, Joshua J. Meeks, ...
177Lu-PSMA-617 addition to ADT and ARPI significantly improved rPFS in PSMA-positive mHSPC patients, with consistent benefits across subgroups. The PSMAddition trial showed a trend toward improved ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
Scott Tagawa, MD, provides an overview of key findings from the PSMAddition study, evaluating 177Lu-PSMA-617 combined with ADT and ARPI in mHSPC. Data from the phase 3 PSMAddition trial (NCT04720157) ...
Nivolumab significantly improves DFS, OS, and DSS in high-risk muscle-invasive urothelial carcinoma, especially in patients with PD-L1 expression ≥1%. The study's 5-year follow-up confirms nivolumab's ...
Enzalutamide plus leuprolide significantly improves overall survival and metastasis-free survival in biochemically recurrent prostate cancer compared to leuprolide alone. Subgroup analysis revealed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback